Johnson & Johnson (JNJ) says Rybrevant Faspro receives US FDA breakthrough therapy designation for patients with advanced head and neck cancer
Importance
Level 1
#JOHNSON & JOHNSON#JNJ.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES